Fisher & Paykel Healthcare Corporation Limited (FSPKF) was downgraded to a Hold Rating at UBS

Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) received a Hold rating and price target from UBS analyst Marcus Curley today. The company's shares closed last Thursday at $20.70.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Curley is ranked #9118 out of 9551 analysts.
In addition to UBS, Fisher & Paykel Healthcare Corporation Limited also received a Hold from Morgan Stanley's David Bailey in a report issued on May 27. However, yesterday, Jefferies upgraded Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) to a Buy.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

2 hours ago

• Bloomberg

Montage Is Said to Hire Banks for $1 Billion Hong Kong Listing

Chinese chip designer Montage Technology Co. has hired banks for its planned Hong Kong listing that could raise about $1 billion, according to people familiar with the matter. The Shanghai-listed company is working with China International Capital Corp., Morgan Stanley and UBS Group AG on the potential share sale, the people said, asking not to be identified because the information isn't public.

Business Insider

3 hours ago

• Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

4 hours ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>